Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Trial Profile

Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Ascites
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors BioVie
  • Most Recent Events

    • 08 Nov 2017 According to a BioVie media release, the second patient has been dosed in this trial. The first patient completed 28 days of treatment with BIV201 and entered the post-therapy observational period last month.
    • 28 Sep 2017 According to a BioVie media release, first patient has been dosed in this trial.
    • 14 Sep 2017 According to a BioVie media release, first patient has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top